Dr. Colleen C. McCormick
Claim this profileLegacy Good Samaritan Hospital and Medical Center
Area of expertise
Ovarian Cancer
Colleen C. McCormick has run 8 trials for Ovarian Cancer. Some of their research focus areas include:
Fallopian Tube Cancer
Colleen C. McCormick has run 7 trials for Fallopian Tube Cancer. Some of their research focus areas include:
Affiliated Hospitals
Legacy Good Samaritan Hospital And Medical Center
Legacy Meridian Park Hospital
Clinical Trials Colleen C. McCormick is currently running
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting
1 award
Phase 2
Robotic vs Open Hysterectomy
for Cervical Cancer
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Recruiting
1 award
N/A
8 criteria
More about Colleen C. McCormick
Clinical Trial Related
6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Colleen C. McCormick has experience with
- Paclitaxel
- Olaparib
- Carboplatin
- Pembrolizumab
- Cediranib Maleate
- Durvalumab
Breakdown of trials Colleen C. McCormick has run
Ovarian Cancer
Fallopian Tube Cancer
Endometrial Adenocarcinoma
Uterine Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Colleen C. McCormick specialize in?
Colleen C. McCormick focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved BRCA1 positive patients, or patients who are Stage IV.
Is Colleen C. McCormick currently recruiting for clinical trials?
Yes, Colleen C. McCormick is currently recruiting for 5 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Colleen C. McCormick has studied deeply?
Yes, Colleen C. McCormick has studied treatments such as Paclitaxel, Olaparib, Carboplatin.
What is the best way to schedule an appointment with Colleen C. McCormick?
Apply for one of the trials that Colleen C. McCormick is conducting.
What is the office address of Colleen C. McCormick?
The office of Colleen C. McCormick is located at: Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon 97210 United States. This is the address for their practice at the Legacy Good Samaritan Hospital and Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.